Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2008-04-18

Last Posted Date: 2020-02-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 59

Registration Number: NCT00661193

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸
Minor and James Medical, PLLC, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 121 locations

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2008-04-17

Last Posted Date: 2023-03-24

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 800

Registration Number: NCT00660842

Locations: 🇮🇹
Ospedale S. Giovanni Calibita Fatebenefratelli, UO di Oncologia, Roma, Italy
🇮🇹
A.O. Univeristaria Policlinico, Modena, Italy
🇮🇹
Ospedale Civile S. Spirito, Pescara, Italy

and more 25 locations

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: stealth liposomal doxorubicin
Drug: carboplatin
Drug: paclitaxel
Drug: Topotecan
Drug: Gemcitabine

First Posted Date: 2008-04-14

Last Posted Date: 2023-11-13

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 215

Registration Number: NCT00657878

Locations: 🇮🇹
Universita Cattolica del Sacro Cuore, Roma, Italy
🇮🇹
Ospedale Mazzoni, Ascoli Piceno, Italy
🇮🇹
Ospedale Senatore Antonio Perrino, Brindisi, Italy

and more 35 locations

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Gemcitabine
Biological: Avastin

First Posted Date: 2008-04-10

Last Posted Date: 2017-07-17

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 39

Registration Number: NCT00655850

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Phase 3

Completed

Conditions: Esophageal Cancer

Interventions: Drug: cetuximab
Drug: cisplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2008-04-10

Last Posted Date: 2022-06-14

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 344

Registration Number: NCT00655876

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
UPMC - Shadyside, Pittsburgh, Pennsylvania, United States

and more 172 locations

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Tumors

Interventions: Drug: Carboplatin
Drug: Fosbretabulin
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2008-04-07

Last Posted Date: 2015-02-09

Lead Sponsor: Mateon Therapeutics

Target Recruit Count: 63

Registration Number: NCT00653939

Locations: 🇺🇸
Pacific Coast Hematology and Oncology Medical Group, Fountain Valley, California, United States
🇺🇸
The Mark H. Zangmeister Center, Columbus, Ohio, United States
🇺🇸
Southbay Oncology Hematology, Campbell, California, United States

and more 12 locations

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Phase 1

Conditions: Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Avastin

First Posted Date: 2008-04-03

Last Posted Date: 2020-08-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 46

Registration Number: NCT00652119

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: ABT-869
Drug: paclitaxel
Drug: Placebo for ABT-869

First Posted Date: 2008-03-27

Last Posted Date: 2013-01-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 10

Registration Number: NCT00645177

Locations: 🇲🇽
Site Reference ID/Investigator# 10181, Durango, DGO., Mexico
🇺🇸
Site Reference ID/Investigator# 8352, San Francisco, California, United States
🇺🇸
Site Reference ID/Investigator# 6920, Harvey, Illinois, United States